Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

Omid Kiamanesh, MD; Steven C. Greenway, MD; Franciscus Dicke, MD, MBA; Brennan Ballantyne, MD; Sasha Mitrovic, RDCS; Kaitlin McGrath, MD; James A. White, MD; William D.T. Kent, MD; Gregor Andelfinger, MD

JACC: Case Reports (Jul 2024)

Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib

Omid Kiamanesh, MD,
Steven C. Greenway, MD,
Franciscus Dicke, MD, MBA,
Brennan Ballantyne, MD,
Sasha Mitrovic, RDCS,
Kaitlin McGrath, MD,
James A. White, MD,
William D.T. Kent, MD,
Gregor Andelfinger, MD

Affiliations

Omid Kiamanesh, MD: Division of Cardiology, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada; Summit Cardiology, Calgary, Alberta, Canada; Address for correspondence: Dr Omid Kiamanesh, Summit Cardiology, 5208-7005 Fairmount Drive SE, Calgary AB T2H 0K4, Canada.
Steven C. Greenway, MD: Departments of Pediatrics and Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada
Franciscus Dicke, MD, MBA: Departments of Pediatrics and Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada
Brennan Ballantyne, MD: Division of Cardiology, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada; Summit Cardiology, Calgary, Alberta, Canada
Sasha Mitrovic, RDCS: Summit Cardiology, Calgary, Alberta, Canada
Kaitlin McGrath, MD: Division of Cardiology, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada
James A. White, MD: Division of Cardiology, Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada; Stephenson Cardiac Imaging Center, Alberta Health Services, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
William D.T. Kent, MD: Section of Cardiac Surgery, Department of Cardiac Sciences, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada
Gregor Andelfinger, MD: Cardiovascular Genetics, Department of Pediatrics, CHU Sainte-Justine, Montreal, Quebec, Canada

Journal volume & issue: Vol. 29, no. 13
p. 102379

Abstract

Read online

RASopathies cause nonsarcomeric hypertrophic cardiomyopathy via dysregulated signaling through RAS and upregulated mitogen-activated protein kinase activity. We provide the first report of the successful treatment of an adult with RAF1-associated hypertrophic cardiomyopathy using trametinib, a MEK inhibitor.

Published in JACC: Case Reports

ISSN: 2666-0849 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-case-reports

About the journal

Abstract

Keywords